BG64125B1 - Полиморфни форми на дофетилид - Google Patents

Полиморфни форми на дофетилид Download PDF

Info

Publication number
BG64125B1
BG64125B1 BG104373A BG10437300A BG64125B1 BG 64125 B1 BG64125 B1 BG 64125B1 BG 104373 A BG104373 A BG 104373A BG 10437300 A BG10437300 A BG 10437300A BG 64125 B1 BG64125 B1 BG 64125B1
Authority
BG
Bulgaria
Prior art keywords
dofetilide
polymorphic
preparation
treatment
pharmaceutically acceptable
Prior art date
Application number
BG104373A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG104373A (en
Inventor
Ian C. Appleby
Trevor J. Newbury
Gary Nichols
Original Assignee
Pfizer Research And Development Company,N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10821150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64125(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Research And Development Company,N.V./S.A. filed Critical Pfizer Research And Development Company,N.V./S.A.
Publication of BG104373A publication Critical patent/BG104373A/xx
Publication of BG64125B1 publication Critical patent/BG64125B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BG104373A 1997-10-27 2000-04-24 Полиморфни форми на дофетилид BG64125B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9722662.5A GB9722662D0 (en) 1997-10-27 1997-10-27 Polymorphs
PCT/EP1998/006641 WO1999021829A1 (en) 1997-10-27 1998-10-09 Dofetilide polymorphs

Publications (2)

Publication Number Publication Date
BG104373A BG104373A (en) 2000-12-29
BG64125B1 true BG64125B1 (bg) 2004-01-30

Family

ID=10821150

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104373A BG64125B1 (bg) 1997-10-27 2000-04-24 Полиморфни форми на дофетилид

Country Status (47)

Country Link
US (1) US6124363A (xx)
EP (1) EP1027329B1 (xx)
JP (1) JP3569495B2 (xx)
KR (1) KR100366167B1 (xx)
CN (1) CN1146537C (xx)
AP (1) AP906A (xx)
AR (1) AR015193A1 (xx)
AT (1) ATE232199T1 (xx)
AU (1) AU737668B2 (xx)
BG (1) BG64125B1 (xx)
BR (1) BR9813308A (xx)
CA (1) CA2307121C (xx)
CO (1) CO4970768A1 (xx)
DE (1) DE69811256T2 (xx)
DK (1) DK1027329T3 (xx)
DZ (1) DZ2632A1 (xx)
EA (1) EA002656B1 (xx)
ES (1) ES2190620T3 (xx)
GB (1) GB9722662D0 (xx)
GT (1) GT199800165A (xx)
HK (1) HK1033933A1 (xx)
HN (1) HN1998000165A (xx)
HR (1) HRP20000247B1 (xx)
HU (1) HUP0004735A3 (xx)
ID (1) ID24658A (xx)
IL (1) IL135435A0 (xx)
IS (1) IS2179B (xx)
MA (1) MA24683A1 (xx)
MY (1) MY123352A (xx)
NO (1) NO325630B1 (xx)
NZ (1) NZ503785A (xx)
OA (1) OA11350A (xx)
PA (1) PA8462001A1 (xx)
PE (1) PE122199A1 (xx)
PL (1) PL197379B1 (xx)
PT (1) PT1027329E (xx)
SA (1) SA98190834B1 (xx)
SI (1) SI1027329T1 (xx)
SK (1) SK5862000A3 (xx)
TN (1) TNSN98193A1 (xx)
TR (1) TR200001135T2 (xx)
TW (1) TW449589B (xx)
UA (1) UA67755C2 (xx)
UY (2) UY25222A1 (xx)
WO (1) WO1999021829A1 (xx)
YU (1) YU24000A (xx)
ZA (1) ZA989719B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (de) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermales Therapeutisches System zur Abgabe von Dofetilid und seine Verwendung
US7326772B2 (en) * 2005-05-12 2008-02-05 Penta Biotech, Inc. Peptide for assaying hERG channel binding
CZ2017772A3 (cs) 2017-12-01 2019-05-29 Farmak, A.S. Způsob přípravy N-[4-(2-{[2-(4-methansulfonamidofenoxy)ethyl](methyl)amino}ethyl)fenyl]methansulfonamidu (Dofetilidu)
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
EP0898964A1 (en) * 1997-08-19 1999-03-03 Pfizer Inc. Method for treating heart failure

Also Published As

Publication number Publication date
PL197379B1 (pl) 2008-03-31
KR100366167B1 (ko) 2003-01-09
UY25341A1 (es) 1999-09-27
PE122199A1 (es) 1999-12-02
HUP0004735A3 (en) 2001-12-28
GB9722662D0 (en) 1997-12-24
UA67755C2 (uk) 2004-07-15
EP1027329A1 (en) 2000-08-16
TNSN98193A1 (fr) 2005-03-15
ES2190620T3 (es) 2003-08-01
GT199800165A (es) 2000-04-19
SK5862000A3 (en) 2001-10-08
PA8462001A1 (es) 2000-05-24
OA11350A (en) 2003-12-17
HK1033933A1 (en) 2001-10-05
DE69811256T2 (de) 2003-09-18
PT1027329E (pt) 2003-04-30
JP3569495B2 (ja) 2004-09-22
BG104373A (en) 2000-12-29
CO4970768A1 (es) 2000-11-07
DZ2632A1 (fr) 2003-03-08
MY123352A (en) 2006-05-31
EP1027329B1 (en) 2003-02-05
NO325630B1 (no) 2008-06-30
BR9813308A (pt) 2000-08-22
AP9801371A0 (en) 1998-12-31
CN1278246A (zh) 2000-12-27
HUP0004735A2 (hu) 2001-10-28
HRP20000247B1 (en) 2002-08-31
ZA989719B (en) 2000-04-26
AU2151299A (en) 1999-05-17
WO1999021829A1 (en) 1999-05-06
IS2179B (is) 2006-12-15
TW449589B (en) 2001-08-11
IL135435A0 (en) 2001-05-20
ID24658A (id) 2000-07-27
DE69811256D1 (de) 2003-03-13
AU737668B2 (en) 2001-08-30
UY25222A1 (es) 2000-12-29
HN1998000165A (es) 1999-02-09
US6124363A (en) 2000-09-26
NO20002191D0 (no) 2000-04-27
TR200001135T2 (tr) 2000-09-21
NZ503785A (en) 2004-11-26
KR20010031439A (ko) 2001-04-16
EA200000365A1 (ru) 2000-12-25
MA24683A1 (fr) 1999-07-01
IS5426A (is) 2000-03-31
NO20002191L (no) 2000-04-27
CN1146537C (zh) 2004-04-21
EA002656B1 (ru) 2002-08-29
AR015193A1 (es) 2001-04-18
CA2307121A1 (en) 1999-05-06
PL340805A1 (en) 2001-02-26
SA98190834B1 (ar) 2006-08-21
SI1027329T1 (en) 2003-04-30
CA2307121C (en) 2006-12-05
YU24000A (sh) 2003-02-28
JP2001521023A (ja) 2001-11-06
AP906A (en) 2000-11-30
HRP20000247A2 (en) 2000-10-31
DK1027329T3 (da) 2003-02-24
ATE232199T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
MXPA04012923A (es) Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
DE69332718T2 (de) Enantiomere von carbazolderivaten als 5-ht1-ähnliche agonisten
DE69112099T2 (de) Kristallinisches Salz von 4-(Di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz[cd]indol.
KR20230021075A (ko) 베타 아드레날린성 작용제의 형태 및 조성물
TW202106680A (zh) Glyt1抑制劑之固體形式
EP3720435B1 (en) Crystal forms and production methods thereof
BG64125B1 (bg) Полиморфни форми на дофетилид
DE69815518T2 (de) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
CN115461344B (zh) 一种glp-1受体激动剂的晶型a及其制备方法
EP0254955B1 (de) Substituierte Pyrido-[2,3-b][1,4]benzodiazepin-6-one, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69324492T2 (de) 1-azaadamantanderivate als 5-ht4 agonisten oder antagonisten und/oder 5-ht3 antagonisten
DE60205504T2 (de) Zitronensäure salz von einer therapeutischen verbindung und deren pharmazeutischen zusammensetzungen
JP4275407B2 (ja) 新規な結晶構造を有するエリスロマイシン誘導体及びその製造方法
JPWO2007126020A1 (ja) Ｎｍｄａ受容体チャネルブロック作用を示す化合物及びそれを用いた薬剤。
MXPA00004059A (en) Dofetilide polymorphs
CZ20001516A3 (cs) Polymorfy dofetilidu
EP0639568A1 (en) Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders
CA2607257A1 (en) Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
PT1641797E (pt) Mesilato de hidrogénio de 4-(4-trans-hidroxicicloexil) amino-2-fenil-7h-pirroloii2,3d] pirimidina e suas formas polimórficas
US20220227712A1 (en) Cholinesterase inhibitor polymorph and application thereof
JP2024501202A (ja) 四置換オレフィン化合物の塩形、結晶及びその製造方法
DE102007032613A1 (de) Spiraprilhydrochlorid und polymorphe Formen davon
CA2456233A1 (en) Paroxetine isethionate salt, process of preparation and use in the treatment of depression
KR20050019792A (ko) 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는조성물, 및(또는) 치료 방법